Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Mycoses 2Leukemia 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Invasive Fungal Infections 1Infections 1Hematologic Neoplasms 1Endometriosis 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1Advanced Solid Tumors 1

Interventions

zanubrutinib 2tirabrutinib 1obinutuzumab 1idelalisib 1Voriconazole 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × B-cell Malignancies × Fluconazole × Clear all
NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡